Search results
Showing 151 to 165 of 1164 results for criteria
Awaiting development Reference number: GID-TA11933 Expected publication date: TBC
Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701]
Awaiting development Reference number: GID-TA11935 Expected publication date: TBC
Awaiting development Reference number: GID-TA11914 Expected publication date: TBC
Awaiting development Reference number: GID-TA11931 Expected publication date: TBC
Awaiting development Reference number: GID-TA11932 Expected publication date: TBC
Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]
Awaiting development Reference number: GID-TA11917 Expected publication date: TBC
Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719]
Awaiting development Reference number: GID-TA11928 Expected publication date: TBC
Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]
Awaiting development Reference number: GID-TA11923 Expected publication date: TBC
Awaiting development Reference number: GID-TA11919 Expected publication date: TBC
Awaiting development Reference number: GID-TA11911 Expected publication date: TBC
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]
Awaiting development Reference number: GID-TA11916 Expected publication date: TBC
Evidence-based recommendations on bevacizumab (Avastin), with a taxane, for treating metastatic breast cancer in adults.
A new model for evaluating and purchasing antimicrobials in the UK
Overview of NICE and NHS England’s pioneering subscription-style purchasing model for antimicrobials: its pilot with ceftazidime-avibactam and cefiderocol in 2022, expansion in 2024, supporting health technology assessments, downloadable guidance and procurement tools.
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over.
Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]
Awaiting development Reference number: GID-TA11954 Expected publication date: TBC